MicroStrategy
MSTR
NVIDIA
NVDA
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
US Stock MarketDetailed Quotes
OLMA Olema Pharmaceuticals
- 6.100
- +0.310+5.35%
Close Dec 20 16:00 ET
- 6.250
- +0.150+2.46%
Post 20:01 ET
450.22MMarket Cap-2.68P/E (TTM)
6.212High5.690Low1.28MVolume5.760Open5.790Pre Close7.73MTurnover3.13%Turnover RatioLossP/E (Static)73.81MShares16.77552wk High2.26P/B250.16MFloat Cap5.55652wk Low--Dividend TTM41.01MShs Float60.270Historical High--Div YieldTTM9.01%Amplitude2.000Historical Low6.032Avg Price1Lot Size
About Olema Pharmaceuticals Company
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
Company Profile
SymbolOLMA
Company NameOlema Pharmaceuticals
Listing DateNov 19, 2020
Issue Price19.00
Founded2006
CEODr. Sean P. Bohen, M.D.
MarketNASDAQ
Employees74
Fiscal Year Ends12-31
Address780 Brannan Street
CitySan Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94103
Phone1-650-243-5555
Websitehttp://www.olema.com
Company Executives
- Name
- Position
- Salary
- Dr. Sean P. Bohen, M.D.
- Director, President and Chief Executive Officer
- 3.15M
- Dr. David C. Myles, PhD
- Chief Discovery and Non-Clinical Development Officer
- --
- Shane Kovacs
- Principal Accounting Officer, Chief Operating and Financial Officer
- 1.55M
- Dr. Naseem Zojwalla, M.D.
- Chief Medical Officer
- 1.30M
- Ian T. Clark
- Chairman of the Board
- 198.65K
- Dr. Cyrus L. Harmon, PhD
- Director
- 1.33M
- Cynthia M. Butitta
- Independent Director
- 180.15K
- Scott Garland
- Independent Director
- 280.21K
- Yi Larson
- Independent Director
- 163.15K
- Andrew S. Rappaport
- Independent Director
- 176.65K
- Dr. Sandra J. Horning, M.D.
- Independent Director
- 158.15K
- Dr. Gorjan Hrustanovic, PhD
- Independent Director
- 165.15K
- Dr. Graham Waley, M.D.,PhD
- Independent Director
- 171.15K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.